scholarly journals A case of seventeen pancreatic metastases from renal cell carcinoma resected by total pancreatectomy

Suizo ◽  
2011 ◽  
Vol 26 (4) ◽  
pp. 517-523
Author(s):  
Eiji HIGAKI ◽  
Naoto GOTOHDA ◽  
Masaru KONISHI ◽  
Shinichiro TAKAHASHI ◽  
Yuichiro KATO ◽  
...  
1996 ◽  
Vol 29 (11) ◽  
pp. 2175-2179 ◽  
Author(s):  
Kazuhide Iwakawa ◽  
Yasushi Matsumoto ◽  
Jyota Watanabe ◽  
Yoshito Ono ◽  
Yasuyuki Shimahara ◽  
...  

Author(s):  
Yujiro Tsuda ◽  
Terumasa Yamada ◽  
Hiroaki Itakura ◽  
Hirotoshi Takayama ◽  
Masami Ueda ◽  
...  

2021 ◽  
Vol 15 (1) ◽  
Author(s):  
Lena Haeberle ◽  
Melanie Busch ◽  
Julian Kirchner ◽  
Georg Fluegen ◽  
Gerald Antoch ◽  
...  

Abstract Background Metastatic spread to the pancreas is a rare event. Renal cell carcinoma represents one possible site of origin of pancreatic metastases. Renal cell carcinoma often metastasizes late and exclusively to the pancreas, suggesting a special role of renal cell carcinoma among primaries metastasizing to the pancreas. Even rarer, renal cell carcinoma may occur simultaneously with pancreatic ductal adenocarcinoma. Case presentation We present the case of a 78-year-old male Caucasian patient with a history of clear-cell renal cell carcinoma treated with oncological left nephrectomy 20 years before. The patient was diagnosed with pancreatic ductal adenocarcinoma by fine-needle aspiration cytology. At our institution, he received neoadjuvant therapy with folic acid, fluorouracil, irinotecan, oxaliplatin for borderline-resectable pancreatic ductal adenocarcinoma, and subsequently underwent total pancreatectomy. Upon resection, pancreatic ductal adenocarcinoma as well as two metachronous metastases of clear-cell renal cell carcinoma occurring simultaneously and cospatially with pancreatic ductal adenocarcinoma were diagnosed in the pancreatic body. Conclusions Renal cell carcinoma metastases of the pancreas are rare and often occur decades after the initial diagnosis of renal cell carcinoma. The combination of renal cell carcinoma metastases and pancreatic ductal adenocarcinoma is even rarer. However, the possibility should be considered by clinicians, radiologists, and pathologists. The special role of renal cell carcinoma as a site of origin of pancreatic metastasis should be further elucidated.


2014 ◽  
Vol 14 (1) ◽  
Author(s):  
Matteo Vincenzi ◽  
Giulio Pasquotti ◽  
Roberta Polverosi ◽  
Claudio Pasquali ◽  
Fabio Pomerri

PLoS ONE ◽  
2016 ◽  
Vol 11 (4) ◽  
pp. e0151662 ◽  
Author(s):  
Paolo Grassi ◽  
Ludovic Doucet ◽  
Palma Giglione ◽  
Viktor Grünwald ◽  
Bohuslav Melichar ◽  
...  

2010 ◽  
Vol 66 (3) ◽  
pp. 275-277
Author(s):  
RA George ◽  
J Debnath ◽  
SS Kumar ◽  
D Banerjee ◽  
R Bhardwaj ◽  
...  

2016 ◽  
Vol 78 (5) ◽  
pp. 37
Author(s):  
O. G. Polushin ◽  
K. V. Fedosenko ◽  
E. V. Ponomareva ◽  
R. E. Topuzov ◽  
O. N. Kislitsyna

2020 ◽  
Vol 38 (6_suppl) ◽  
pp. 695-695
Author(s):  
Brice Chanez ◽  
Fabrice Caillol ◽  
Jean-Philippe Ratone ◽  
Erwan Bories ◽  
Christian Pesenti ◽  
...  

695 Background: Pancreatic metastases (PM) from renal cell carcinoma (RCC) are rare but associated with long survival. The usual management of PM is surgery or tyrosine kinase inhibitor (TKI) with sides effects. Endoscopic radiofrequency ablation (EUSRFA) is an innovative approach to focally treat deep metastasis and could be a relevant technic to control PM from RCC. Methods: This analysis addressed the local control and toxicity in patients treated by EUSRFA for progressive PM from RCC. EUSRFA was done with a linear EUS scope and a 19 G needle delivering short ablation time. Response was assessed by CT-scan using both size and contrast enhancement of the PM treated every 2 to 3 months. Results: 8 pts from Paoli-Calmettes Institute (France) were treated between May 2017 and August 2019. Age was 70.5y [61-75], 5/8 female, ECOG 0-1 (100%). The median time from diagnosis to PM was 14.5 years [9.35-22.18], median number of PM was 2 [1-3], 6/8 was documented by histology and all were classified as progressive before EUSRFA. PM localizations was: head in 40%, body 40% and average size was 14 mm [4 - 35]. 75% of pts (6/8) had other mRCC spread, 5/8 had received systemic treatment and 2 were on therapy at EUSRFA time. 3 pts had EUSRFA as the only treatment for RCCm. We performed 18 EUSRFA procedures over 16 PM. Patient received in median 2 EUSRFA sessions [1-3]. Follow up of 22.4 months [2.3-42.6], 50% of treated PM was evaluated as complete response, 17.5% as partial response and 20% as stable disease at the last CT-scan evaluation. 2 pts were considered as progressive disease and PM focal control was 87.5%. One patient treated with TKI during EURFA developed a paraduodenal abscess 2 months after EUSRFA. Another patient with biliary prothesis developed hepatic abscesses few days after EUSRFA. No other acute side effects were experienced. Interestingly, all PM treated with diameter of < 20mm was locally control versus only 75% of PM> 20mm. Conclusions: Though larger studies have to corroborate our data, EUSRFA is feasible and displays a good local control for PM. It could be a valuable option, less morbid than pancreas resection, for well selected patients with progressive PM.


Sign in / Sign up

Export Citation Format

Share Document